Clinical Features and Outcomes of Hospitalized Solid Organ Transplant and Hematopoietic Stem Cell Recipients with Sars- CoV-2 Infection in the Midwestern United States: A Multi-Center Retrospective Cohort Study
American Journal of Transplantation
; 22(Supplement 3):644-645, 2022.
Article
in English
| EMBASE | ID: covidwho-2063525
ABSTRACT
Purpose:
Immunocompromised hosts are at risk for severe complications or death from SARS-CoV-2 infection. Few studies describe the clinical features, outcomes and treatment strategies in this population across multiple sites. Method(s) A multi-center retrospective analysis from academic medical centers in the Midwestern US was conducted for hospitalized patients with SARS-CoV-2 infection. Data was collected electronically using standardized intake and 28-day follow up case report forms. The centers included Northwestern University, University of Nebraska, Cleveland Clinic, University of Chicago, Indiana University and University of Kansas. Result(s) The cohort included 272 patients hospitalized from March 2020 to November 2021. Demographics are in Table 1. Mean admission was 6.84 +/- 6.42 days after symptom onset. The most commonly reported symptoms were cough (71.4%), dyspnea (59.6%), fatigue (55.3%), fever (54.9%), and diarrhea (43.9%). Admission CXR had pneumonia in 31.6%;63% with multifocal or patchy opacities. 87 patients had a chest CT;72 (82.7%) showed pneumonia. 97 patients (36.1%) required ICU admission. Treatments included remdesivir (58.5%), dexamethasone (54.4%), convalescent plasma (3.0%), IL-6 inhibitor (4.5%). Immunosuppression management included holding (44.2%) or decreasing (26.6%) the dose of antimetabolite. 76 patients (28.3%) had documented bacterial co-infection, in blood (34.1%), lung (30.6%) and urine (30.6%). 6 (2.2%) patients experienced rejection within 30 days and 8 patients (3.0%) developed CMV viremia. 26 patients (9.7%) died by day 28. Conclusion(s) This cohort had high rates of ICU admission (36.1%), bacterial coinfection (28.3%), rehospitalization (31.5%) and mortality (9.7%).
adult; clinical feature; cohort analysis; coinfection; conference abstract; coronavirus disease 2019; coughing; demographics; diarrhea; drug therapy; dyspnea; fatigue; female; fever; follow up; hematopoietic stem cell; hospital patient; hospital readmission; human; human cell; human tissue; Illinois; immunosuppressive treatment; Indiana; Kansas; major clinical study; male; mortality; Nebraska; outcome assessment; pneumonia; retrospective study; surgery; thorax; United States; university hospital; viremia; antimetabolite; convalescent plasma; dexamethasone; endogenous compound; interleukin 6; remdesivir
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Language:
English
Journal:
American Journal of Transplantation
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS